Identfication of tumor-specific and tumor-associated antigens for potential clinical application in vaccination studies - Part: Squamous cell cancer of the head and neck

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00014018

Enrollment

Registered

2018-02-14

Start date

2018-01-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C32 C10

Interventions

Group 1: Patient with squamous cell cancer of the head and neck with indication for surgical resection. Tumor- and adjacent non-malignant material, as well as peripheral blood are obtained for laborat

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Squamous cell carcinoma of the head and neck with indication for surgical resection

Exclusion criteria

Exclusion criteria: - Relevant comorbidities - no indication for surgery - insufficient amount of tumor material

Design outcomes

Primary

Measure	Time frame
Identification of HLA-presented tumor-associated and/or tumor-specific ligands (HLA-ligandome)	—

Secondary

Measure	Time frame
- Evaluation of the immunological relevance of the identified ligands - Evaluation of metabolic pathways	—

Countries

Germany

Contacts

Public ContactSarah;Paul-Stefan Schröder;Mauz

Universitäts HNO-Klinik;Universitätsklinik für Hals-, Nasen- und Ohrenheilkunde

sarah.schroeder@med.uni-tuebingen.de;paul-stefan.mauz@med.uni-tuebingen.de+49-7071-29-88088;+49-7071-29-88088

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026